Atlas Trials

A Dose Escalation Phase 1 Study Evaluating the Safety and Pharmacokinetics of an Inhaled COVID-19 Inhibitor Delcetravir in Healthy Subjects

Clinical trial NCT05453279 · UNKNOWN

Trial details

NCT number
NCT05453279
Sponsor
Esfam Biotech Pty Ltd
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
COVID-19
Start date
2022-09-01
Primary completion
2022-11-01
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.